Advertisement

Multiple Myeloma: Role of Magnetic Nanoparticles

  • Raghvendra A. BoharaEmail author
  • Priyanaka Singh
Chapter
  • 38 Downloads
Part of the Nanomedicine and Nanotoxicology book series (NANOMED)

Abstract

With rapid progress in nanomedicine, magnetic nanoparticles (MNPs) have been proved as a promising theranostics tool in biomedical applications including diagnostic imaging, drug delivery, and novel therapeutics. Multiple myeloma is a hematological malignancy with relapse rate greater than 90%. Limitations in the treatment of MM are the serious side effects caused by drugs used in chemotherapy. The emphasis in cancer treatment has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted and rationally designed therapies showing greater efficacy with fewer side effects. Nanomedicine may help to address these issues and a revolutionary treatment. Here, we explained brief insights of MM, the key pathways that play a vital role in the development of the disease and the role of magnetic nanoparticles in the diagnosis and treatment of the MM.

Keywords

Magnetic nanoparticles Multiple myeloma Targeted drug delivery Novel therapy 

Notes

Acknowledgements

This research is supported by Irish Research council under the Government of Ireland Postdoctoral fellowship Grant GOIPD/2017/. The funding agencies is  gratefully acknowledged.

References

  1. Agarwal A, Mahadevan D (2013) Novel targeted therapies and combinations for the treatment of multiple myeloma. Cardiovasc Hematol Disord-Drug Targets 13(1):2–15.  https://doi.org/10.2174/1871529x11313010002CrossRefGoogle Scholar
  2. Alexanian R, Delasalle K, Wang M (2013) High frequencies of response after limited primary therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 13(2):119–122.  https://doi.org/10.1016/j.clml.2012.11.008CrossRefGoogle Scholar
  3. Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D et al (2010) Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br J Haematol 148(4):562–568.  https://doi.org/10.1111/j.1365-2141.2009.07981.x
  4. Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA (2017) Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Manag Res 9:307–314.  https://doi.org/10.2147/CMAR.S117477CrossRefGoogle Scholar
  5. Cole AJ, Yang VC, David AE (2011) Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol 29(7):323–332.  https://doi.org/10.1016/j.tibtech.2011.03.001CrossRefGoogle Scholar
  6. Detappe A, Bustoros M, Mouhieddine TH, Ghoroghchian PP (2018) Advancements in nanomedicine for multiple myeloma. Trends Mol Med 24(6):560–574.  https://doi.org/10.1016/j.molmed.2018.04.005CrossRefGoogle Scholar
  7. Fairfield H, Falank C, Avery L, Reagan MR (2016) Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci 1364(1):32–51.  https://doi.org/10.1111/nyas.13038CrossRefGoogle Scholar
  8. Firer MA, Gellerman G (2012) Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 5(1):1.  https://doi.org/10.1186/1756-8722-5-70CrossRefGoogle Scholar
  9. Gertz MA, Vincent Rajkumar S (2014) Multiple myeloma: diagnosis and treatment. Multiple Myeloma Diagn Treat 91(1):1–311.  https://doi.org/10.1007/978-1-4614-8520-9CrossRefGoogle Scholar
  10. Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, et al (2019) Immunotherapy in multiple myeloma: accelerating on the path to the patient. Clin Lymphoma, Myeloma and Leuk.  https://doi.org/10.1016/j.clml.2019.02.004
  11. Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ (2018) CAR T cell therapy for multiple myeloma: where are we now and where are we headed? Leuk Lymphoma 59(9):2056–2067.  https://doi.org/10.1080/10428194.2017.1393668CrossRefGoogle Scholar
  12. Hayashi K, Nakamura M, Miki H, Ozaki S, Abe M, Matsumoto T, Sakamoto W, Yogo T, Ishimura K (2014) Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics 4(8):834–844.  https://doi.org/10.7150/thno.9199CrossRefGoogle Scholar
  13. Huang Y-W, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R (1999) Current drug therapy for multiple myeloma. Drugs 57(4):485–506.  https://doi.org/10.2165/00003495-199957040-00004CrossRefGoogle Scholar
  14. Huang J, Li Y, Orza A, Lu Q, Guo P, Wang L, et al (2016) Magnetic nanoparticle facilitated drug delivery for cancer therapy with targeted and image-guided approaches. Adv Funct Mater 26(22):3818–3836.  https://doi.org/10.1002/adfm.201504185
  15. Kemp JA, Shim MS, Heo CY, Kwon YJ (2016) “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev 98:3–18.  https://doi.org/10.1016/j.addr.2015.10.019CrossRefGoogle Scholar
  16. Kenealy MK, Prince HM, Hönemann D (2006) Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy 26(8 I):1205–1206.  https://doi.org/10.1592/phco.26.8.1205
  17. Kyle RA, Rajkumar SV (2011) ASH 50th anniversary review multiple myeloma. Bone 111(6):2962–2972Google Scholar
  18. Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Controlled Release 161(2):175–187.  https://doi.org/10.1016/j.jconrel.2011.09.063CrossRefGoogle Scholar
  19. Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M (2017) Emerging drugs and combinations to treat multiple myeloma. Oncotarget 8(36):60656–60672.  https://doi.org/10.18632/oncotarget.19269
  20. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al (2017) Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol 3(7):980–988. http://doi.org/10.1001/jamaoncol.2016.3350
  21. Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12(5):335–348.  https://doi.org/10.1038/nrc3257CrossRefGoogle Scholar
  22. Musto P, Montefusco V (2016) Are maintenance and continuous therapies indicated for every patient with multiple myeloma? Exp Rev Hematol 9(8):743–751.  https://doi.org/10.1080/17474086.2016.1196127CrossRefGoogle Scholar
  23. Oranger A, Carbone C, Izzo M, Grano M (2013) Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol 29:2013Google Scholar
  24. Pantani L, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, Rocchi S et al (2016) Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Exp Rev Hematol 9(3):315–323. http://doi.org/10.1586/17474086.2016.1127754
  25. Ramakrishnan V, D’Souza A (2016) Signaling pathways and emerging therapies in multiple myeloma. Curr Hematol Malignancy Rep 11(2):156–164.  https://doi.org/10.1007/s11899-016-0315-4CrossRefGoogle Scholar
  26. Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, et al (2011) Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 154(6):755–762. http://doi.org/10.1111/j.1365-2141.2011.08791.x
  27. Rushworth GF, Leslie SJ, Forsyth P, Vincent C (2012) Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. Ther Adv Drug Saf 3(3):115–122.  https://doi.org/10.1177/2042098611433773CrossRefGoogle Scholar
  28. Saunders G (2005) Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract 11(3):83–100.  https://doi.org/10.1191/1078155205jp160oaCrossRefGoogle Scholar
  29. Shamsi M, Sedaghatkish A, Dejam M, Saghafian M, Mohammadi M, Sanati-Nezhad A (2018) Magnetically assisted intraperitoneal drug delivery for cancer chemotherapy. Drug Deliv 25(1):846–861.  https://doi.org/10.1080/10717544.2018.1455764CrossRefGoogle Scholar
  30. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34.  https://doi.org/10.3322/caac.21551
  31. Soenen SJ, De Cuyper M (2010) Assessing iron oxide nanoparticle toxicity in vitro: current status and future prospects. Nanomedicine 5(8):1261–1275. http://doi.org/10.2217/nnm.10.106
  32. Štifter S, Babarovic V, Valkovic T, Bekafigo IS, Štemberger C, Načinovic N, Lucin K, Jonjić N (2010) Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiplemyeloma. Diagn Pathol 5(30):1–7. http://www.diagnosticpathology.org/content/5/1/30
  33. Tietze R, Zaloga J, Unterweger H, Lyer S, Friedrich RP, Janko C et al (2015) Magnetic nanoparticle-based drug delivery for cancer therapy. Biochem Biophys Res Commun 468(3):463–470. http://doi.org/10.1016/j.bbrc.2015.08.022
  34. Tzakos AG, Briasoulis E, Thalhammer T, Jäger W, Apostolopoulos V (2013) Novel oncology therapeutics: targeted drug delivery for cancer. J Drug Deliv 2013:1–5.  https://doi.org/10.1155/2013/918304CrossRefGoogle Scholar
  35. Usmani SZ, Chiosis G (2011) HSP90 inhibitors as therapy for multiple myeloma. Clin Lymphoma, Myeloma Leuk 11(Suppl.1):S77–S81.  https://doi.org/10.1016/j.clml.2011.03.027
  36. Varshosaz J, Farzan M (2015) Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 21(42):12022CrossRefGoogle Scholar
  37. Wagner A, Knipe J, Orive G, Peppas N (2019) Quantum dots in biomedical applications. Acta Biomater 94:44–63.  https://doi.org/10.1016/j.actbio.2019.05.022CrossRefGoogle Scholar
  38. Wang M, Thanou M (2010) Targeting nanoparticles to cancer. Pharmacol Res 62:90–99. http://doi.org/10.1016/j.phrs.2010.03.005
  39. Wong SW, Comenzo RL (2015) CD38 monoclonal antibody therapies for multiple myeloma. Clin Lymphoma Myeloma Leuk 15(11):635–645.  https://doi.org/10.1016/j.clml.2015.07.642CrossRefGoogle Scholar
  40. Ying E, Hwang HM (2010) In vitro evaluation of the cytotoxicity of iron oxide nanoparticles with different coatings and different sizes in A3 human T lymphocytes. Sci Total Environ 408(20):4475–4481.  https://doi.org/10.1016/j.scitotenv.2010.07.025CrossRefGoogle Scholar
  41. Zhou Y, Wang R, Teng Z, Wang Z, Hu B, Kolios M et al (2016) Magnetic nanoparticle-promoted droplet vaporization for in vivo stimuli-responsive cancer theranostics. NPG Asia Mater 8(9):e313–e318. http://doi.org/10.1038/am.2016.146

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Centre for Interdisciplinary Research, D. Y. Patil UniversityKolhapurIndia
  2. 2.CÚRAM, SFI, Center for Research in Medical Devices, National University of Ireland Galway, IrelandGalwayIreland

Personalised recommendations